2Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J, 1991,121(6 Pt 1):1852-1853.
3Vasan RS, Stahl RA, Schwietzer G. The progression from hypertension to congestive heart failure . JAMA, 1996, 275: 1604-1606.
4Guidelines Subcommittee. 1999 World Health Organization-international society of hypertension Guidelines for the Management of Hypertension. J Hypertens,1999,17: 151-183.
5Little WC,Downes TR. Clinical evaluation of left ventricular diastolic performance. Prog Cardiovasc Dis, 1990, 32:273-290.
6Okin PM, Devereux RB, Jem S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation, 2003,12; 108: 684-690.
7Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the pros
8Sheridan DJ. Left ventricular hypertrophy regression: the LIVE trial.Cardiologia,1999,44 Suppl 1(Pt 2):541-543.
9Kannel WB,Castelli WP, McNamara PM,et al. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med, 1972,287:781-787.
10WU ZJ, Qian XX, Cai DH, et al. Long - term oral administration of L - arginine enhance endothelium - depedent vasorelaxation and inhibits neointimal thickening after endethelial denudation inrats. Clin Med J, 1996;109(8):592.
